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Abstract
Background: Analogues of vitamin D3 are extensively used in the treatment of various illnesses, such as
osteoporosis, inflammatory skin diseases, and cancer. Functional testing of new vitamin D3 analogues and
formulations for improved systemic and topical administration is supported by sensitive screening methods that
allow a comparative evaluation of drug properties. As a new tool in functional screening of vitamin D3 analogues,
we describe a genomically integratable sensor for sensitive drug detection. This system facilitates assessment of the
pharmacokinetic and pharmadynamic properties of vitamin D3 analogues. The tri-cistronic genetic sensor encodes
a drug-sensoring protein, a reporter protein expressed from an activated sensor-responsive promoter, and a
resistance marker.
Results: The three expression cassettes, inserted in a head-to-tail orientation in a Sleeping Beauty DNA transposon
vector, are efficiently inserted as a single genetic entity into the genome of cells of interest in a reaction catalyzed
by the hyperactive SB100X transposase. The applicability of the sensor for screening purposes is demonstrated by
the functional comparison of potent synthetic analogues of vitamin D3 designed for the treatment of psoriasis and
cancer. In clones of human keratinocytes carrying from a single to numerous insertions of the vitamin D3 sensor, a
sensitive sensor read-out is detected upon exposure to even low concentrations of vitamin D3 analogues. In
comparative studies, the sensor unveils superior potency of new candidate drugs in comparison with analogues
that are currently in clinical use.
Conclusions: Our findings demonstrate the use of the genetic sensor as a tool in first-line evaluation of new
vitamin D3 analogues and pave the way for new types of drug delivery studies in sensor-transgenic animals.
Background
T h ea c t i v ef o r mo fv i t a m i nD 3 ,1 a,25-dihydroxyvitamin
D3 (also known as calcitriol), belongs to the family of
steroid hormones and has long been known for its pivo-
tal role in calcium and phosphate homeostasis, bone
metabolism, and regulation of cell growth in skin [1].
However, accumulating evidence suggests a much
broader range of biological actions of calcitriol including
differentiation, proliferation, and apoptosis of a wide
range of cell types [2,3]. Hence, vitamin D3 deficiency
has been associated with cancer development, loss of
renal function, cardiovascular disease, and deregulation
of immune function, supporting the role of vitamin D3
derivatives as potent antiproliferative and therapeutic
agents [4,5].
Calcitriol exerts its role by binding to the ubiquitous
nuclear vitamin D receptor (VDR) (see figure 1A for
schematic overview). VDR, a trans-acting transcription
factor belonging to the superfamily of nuclear hormone
receptors [6,7], is constituted of five functional domains
including an N-terminal DNA binding domain (DBD), a
C-terminal ligand binding domain (LBD) and a tran-
scription factor interaction interface. Circulating vitamin
D3 is bound by vitamin D binding protein (DBP).
Transport across the cellular membrane is mediated by
diffusion or megalin-mediated endocytosis prior to
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proteins (IDBPs) within the cytoplasm. Upon ligand
binding, VDR undergoes a conformational change that
allows interaction with other cellular proteins. The
VDR-ligand complex is transported across the nuclear
membrane and then forms a nuclear heterodimeric
complex with the retinoid X receptor (RXR). The
ligand-bound VDR-RXR complex recruits coactivators
that may induce chromatin remodeling by inducing his-
tone acetylation. VDR-RXR recognizes genomic VDR
target sequences known as vitamin D response elements
(VDREs) [8] and activates transcription by recruiting
basal transcription factors, such as TFIIB, TATA-bind-
ing protein (TBP) and transcription-associated factors
(TAFs), and RNA polymerase II [9]. VDRE motifs are
found in large subset of genes that are potentially regu-
lated by the receptor complex. Ligand-activated VDR
predominately acts as a transcription inducer, but is also
implicated in repression pathways by masking promoter
sequences through bindingo fV D R Es i t e s .G r o w t h -
promoting genes, like c-myc, may be repressed by such
mechanisms [10], whereas certain interleukins, including
IL-8 and IL-12, may be amenable to this type of regula-
tion through repression of NF-kappaB-directed tran-
scriptional activation [11-13].
The antiproliferative actions of calcitriol have
prompted the development of calcitriol and synthetic
vitamin D3 analogues as new drugs for treatment for
various disorders including secondary hyperparathyroid-
ism in chronic kidney disease, various cancers, osteo-
porosis, and hyperproliferative conditions in the skin
(reviewed in [14]). Vitamin D therapy is well-established
in autoimmune skin diseases, and analogues of Vitamin
D3 currently represent the most frequently prescribed
drugs for topical treatment of mild and moderate
inflammation of the skin. The pathogenesis of psoriasis,
a common chronic inflammatory skin disease, is inher-
ently complex and characterized by alterations of var-
ious cell types. Activated skin-homing lymphocytes
trigger release of cytokines and growth factors, leading
Figure 1 A genetic sensor system for detection of vitamin D analogues. (A) Mechanism of transcriptional activation mediated by vitamin
D3. DBP, vitamin D binding protein; IDBP, intracellular vitamin D binding proteins (IDBPs); VDR, vitamin D receptor (VDR); RXR, retinoid X
receptor; VDRE, vitamin D response element. (B) Schematic representation of the components of the sensor and mode of action. Promoters are
presented as light grey arrows. (C) Effect of calcipotriol and alfacalcidol on cell survival at different concentrations. HaCaT cells were
supplemented drug at various concentrations, demonstrating reduced in vitro survival at concentrations ≥10
-5 M. Surviving colonies were stained
and counted after 8 days. The data are shown as mean values ± standard deviations. A square (#) indicates the level of survival of untreated
cells, whereas stars (*) indicate evident change in morphology. The broken line indicates the maximum concentration employed in subsequent
experiments. (D) Receptor and sensor function under transient transfection conditions. HEK293 cells were co-transfected with 1.5 μg pT2/UAS-
d2eGFP.SV40-neo together with 0.5 μg pGal4VP16 or pMhVDR. The cells were left untreated or exposed to DMSO-dissolved alfacalcidol or
calcipotriol at different concentrations (as indicated below the x-axis) 24 hours after transfection. After an additional 48 hours the cells were
analyzed by flow cytometry. Expression of d2eGFP in untreated cells was set to 1 (left column). Representative fluorescence microscopy pictures
(at 16X magnification; 48 hours after drug supplementation) of relevant combinations of transfected plasmids and drug treatment (as indicated
in the table) are shown at the bottom.
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vascular dilation as well as keratinocyte hyperprolifera-
tion leading to hyperkeratosis [15-19]
Calcitriol, or synthetic derivatives, control skin home-
ostasis by regulating keratinocyte proliferation and differ-
entiation [20-22] through antiproliferative mechanisms
that include a variety of growth-regulating pathways,
including Erk/MAPK and phosphoinositide 3-kinase/
AKT signaling, that in turn suppress expression of DNA
replication genes [23]. Calcitriol-induced repression of
keratinocyte growth is accompanied by expression of dif-
ferentiation markers such as transglutaminase and invo-
lucrin and formation of cornified envelopes [24,25]. In
addition, topical application of vitamin D3 analogues
may induce apoptosis of psoriatic keratinocytes [26]. The
immunemodulatory actions of vitamin D3 derivatives
may include transcriptional repression of cytokine pro-
duction [11-13] and regulation of antigen-presenting cell
functions and the capacity to modulate the T-cell reper-
toire and T-helper cell responses in skin [27].
The broad therapeutic potential of vitamin D3 com-
pounds has triggered a search for new engineered com-
pounds with improved specificity and high VDR affinity
and which do not cause side-effects such as hypercalce-
mia, soft tissue calcification and bone resorption upon
systemic administration [28]. Although topically applied
vitamin D3 analogues are typically well tolerated and
adverse effects seem confined to mild irritant dermatitis
and only in rare cases hypercalcemia [29,30], not all
psoriasis-affected individuals respond to the treatment.
Disparities between vitamin D3 analogues and their bio-
logical properties may reflect specific VDR binding
properties and small differences in the conformational
changes of ligand-bound VDR. In different cell types,
such small variations may potentially influence the
interaction between the VDR-RXR complex with co-
activators and co-repressors [31], ultimately causing
differences in patterns of transcriptional modulation.
The efficacy of vitamin D3 analogues is increased with
optimized cellular uptake, improved drug stability, high
VDR affinity, and induction of ideal conformational
changes in VDR. With the purpose of screening new
drugs with respect to such parameters, we present here
a novel technology for genetically based sensoring and
functional screening of vitamin D3 analogues. By use of
a genomically integratable bipartite sensor that contains
both sensor and reporter modules expressed from a sin-
gle genetic entity, we can monitor cellular administra-
tion and function in any cell type of interest. This type
of sensor allows direct comparison of engineered vita-
min D3 compounds in different cellular contexts and
establishes a platform for studies of drug delivery in vivo
by constructing transgenic animals with the sensor
system.
The genetic sensor combines the well-characterized
Gal4-UAS transcriptional system discovered in Sacchar-
omyces cerevisiae [32] and the effective Sleeping Beauty
(SB) Tc1-like transposable element reconstructed from
teleost fish [33]. SB is a ‘cut-and-paste’ transposable ele-
ment that has been developed as a gene-inserting vector
for gene therapy and transgenesis [34]. As a major
advantage, SB can accommodate various individual
expression cassettes that are, in the context of the trans-
poson vector, inserted into the genome in a reaction
catalyzed by the SB transposase. Here, we describe the
efficient mobilization and high sensitivity of a tri-cistro-
nic SB-derived sensor expressing (i) a sensor protein,
driven by a keratinocyte-specific promoter, consisting of
the ligand binding domain (LBD) of the vitamin D
receptor (VDR) fused to the Gal4 DNA-binding domain
(DBD), (ii) a destabilized eGFP reporter protein
(d2eGFP) driven by a Gal4-responsive promoter, and
(iii) a selection marker gene, neo, driven by the simian
virus 40 (SV40) promoter. In DNA transposon-contain-
ing keratinocytes, the integrated sensor exhibits a sensi-
tive in vitro response to vitamin D3 analogues and
facilitates a direct functional comparison of a set of syn-
thetic analogues, some of which are currently in clinical
use. This approach allows comparative studies of drug
binding affinity, activity and delivery and may serve as a
first-line tool for evaluation of new vitamin D3 analo-
gues and as a transgenic marker for drug delivery in
sensor-transgenic animals.
Results
Genetic sensoring of vitamin D analogues alfacalcidol and
calcipotriol
To develop a sensoring system for sensitive detection of
vitamin D3 analogues, we first established separate sen-
sor and reporter vectors for drug detection by transient
expression in transfected cell lines. In the sensor con-
struct, a fusion protein containing the ligand binding
domain (LBD) of the human vitamin D receptor (hVDR)
fused to the Gal4 DNA-binding domain (DBD) was
expressed from an SV40 promoter, whereas the reporter
plasmid contained a reporter gene expressing the destabi-
lized eGFP protein (d2eGFP) from a Gal4-responsive
promoter (UAS-TK) (figure 1B). The sensor design was
based on previous findings suggesting that the hVDR,
upon binding by the ligand, forms heterodimers with
RXR protein and via the DBD domain binds to the Gal4-
responsive element UAS [35]. Here, transcription factors
are recruited due to the ligand-induced conformational
change of hVDR, thus leading to transcription of the
d2eGFP gene (figure 1B). Given the inherent rapid turn-
over of d2eGFP (half life of approximately 2 hours), the
signal intensity and sustainability is suspected to depend
on ligand dose, stability and binding kinetics.
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derivates with modifications in the side chain. Calcipo-
triol is an approved psoriasis-treating drug marketed
under the trade name Dovonex
®, whereas alfacalcidol,
marketed under the trade name One-Alpha
®,i su s e d
in the management of vitamin D deficiencies such as
osteomalacia [36,37]. These well characterized com-
pounds were therefore utilized in the initial tests of
the sensor. Using the HaCaT keratinocyte cell line as
a model system, we first wanted to define an in vitro
working range for the two compounds. A kill-curve
was constructed based on a relative survival rate of
naive HaCaT cells, cultured in the presence of either
calcipotriol or alfacalcidol in concentrations ranging
from 10
-7 Mt o1 0
-4 M, compared to a no drug con-
trol (figure 1C). The cells were indifferent to concen-
trations below 10
-5 M for calcipotriol and below 2.5 ×
10
-5 M for alfacalcidol above which a marked change
in morphology (data not shown) and a dramatic
increase in apoptosis was evident. Thus, for the suc-
ceeding studies of drug detection a maximum concen-
tration of 10
-5 M was used which is comparable to in
vitro experimental concentrations used by others
[38,39].
Next, HEK-293 cells were transfected transiently
with the two plasmids encoding sensor and reporter
proteins, respectively, and treated with calcipotriol or
alfacalcidol. As a positive control, we also co-trans-
fected cells with the d2eGFP reporter construct
together with a plasmid expressing a constitutively
active transcriptional activator consisting of Gal4-DBD
fused with the herpes simplex virus-derived virus pro-
tein 16 (VP16). Transfected cells were analyzed by
flow cytometry two days after transfection. As shown
in figure 1D, d2eGFP expression was markedly
increased by the presence of the Gal4VP16 activator,
demonstrating VP16-directed induction of transcrip-
tion from the UAS-TK promoter. Also as expected,
cells transfected only with the d2eGFP reporter plas-
mid were in general negative for expression of the
reporter protein, although a vague background of
d2eGFP expression could be detected (data not shown)
indicative of limited leakiness of the UAS-TK promo-
ter. With increasing concentrations of calcipotriol and
alfacalcidol, expression of d2eGFP was induced in cells
co-transfected with both sensor and reporter plasmids.
For calcipotriol, the reporter was activated at the high-
est analyzed drug concentration (10
-6 M). Alfacalcidol
activated the sensor system most potently, and robust
d2eGFP induction could be monitored with a drug
concentration of 10
-8 Ma n de v e n1 0
-10 M (figure 1D).
In summary, these findings provided evidence of the
detection of a cellular uptake of vitamin D3 analogues
by a split two-component genetic sensor system.
Generation of a vitamin D sensor-reporter platform in a
SB DNA transposon vector
The SB DNA transposon system facilitates efficient host
genome integration of genetic cargo with a total size of
more than 10 kb. The unique properties of SB as a ‘cut-
and-paste’ DNA transposon allow transposase-directed
co-mobilization of a set of separate gene cassettes, each
carrying their own promoter, contained in the context
of a single transposon vector. As a result, the gene cas-
settes are inserted side-by-side in a single chromosomal
locus. Conventional integrating viral vectors may not as
easily be modified to contain three gene cassettes since
viral transduction may be inhibited by the presence of
several promoters and the length of the construct. To
engineer an integratable genetic sensor, we constructed
a tri-cistronic SB vector (designated pT2/UAS-d2eGFP.
SV40-neo.K14-Gal4hVDR) accommodating (i) the UAS-
d2eGFP reporter driven by the UAS-TK promoter, (ii) a
neomycin resistance gene expressed from an SV40 pro-
moter, and (iii) the Gal4hVDR sensor expressed from a
keratin 14 (K14) promoter (figure 2A). Use of the K14
promoter would confine expression of the sensor pro-
tein to cell types with a keratinocyte origin such as the
human keratinocyte cell line HaCaT (K14 activity veri-
fied by RT-qPCR, data not shown), or in vivo to the
stratum basale of the epidermis.
The transposition efficiency of the tri-cistronic SB vec-
tor was evaluated by transfecting HaCaT cells with 1.7
μg pT2/UAS-d2eGFP.SV40-neo.K14-Gal4hVDR together
with 15, 50 or 300 ng of transposase-encoding plasmid.
A panel of five transposase plasmids (pCMV-mSB,
pCMV-SB10, pCMV-HSB3, pCMV-HSB16, and pCMV-
SB100X) was utilized encoding transposases of varying
functional potencies ranging from the inactive mutated
mSB to the hyperactive SB100X variant. The different
transposases were expressed from otherwise identical
plasmids by the CMV promoter.
Numbers of G418-resistant colonies (figure 2B) indi-
cated that the neo expression cassette was inserted
markedly more frequently in the presence of active
transposases relative to the inactive mSB, indicating that
genomic integration of the tri-cistronic vector was effi-
ciently accomplished by a transposase-directed mechan-
ism. Using a medium dose (50 ng) of transposase-
encoding plasmid the relative activity of the five trans-
posase variants was as follows: mSB < SB10 < HSB3 <
HSB16 < SB100X. In contrast, in the higher-dose experi-
ment (300 ng plasmid) the presence of HSB16 resulted
in the highest number of colonies. This finding was a
likely indication of an inhibitory effect of increased con-
centrations of the transposase (a phenomenon referred
to as ‘overproduction inhibition’ [40]) when SB vector
insertion was catalyzed by SB100X. At a low transposase
dosage (15 ng plasmid) the transposition efficiency was
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SB100X was most pronounced at this dosage (65-fold
difference, p = 0.0043). Also, the concentration of mSB
seemed to influence the rate of random integration. Pro-
vided the widely accepted fact that mSB is catalytically
inactive, this finding suggested that mSB to a limited
degree supported random plasmid insertion.
Detection of Vitamin D3 analogues by integrated SB
sensor
To evaluate the sensor capacity of the integrated tri-cistro-
nic sensor-reporter system, we first tested a population of
pooled G418-resistant HaCaT clones stably transfected
with pT2/UAS-d2eGFP.SV40-neo.K14-Gal4hVDR for
responsiveness to calcipotriol and alfacalcidol (figure 3A).
Exposure to the drug resulted in a significant increase in
fluorescence in a concentration-dependent manner. Thus,
at 10
-5 M alfacalcidol the percentage of d2eGFP-positive
cells was roughly 43 times higher than without the drug (p
≤ 0.0001), about 38 times higher than at a concentration
of 10
-7 M( p≤ 0.0001) and roughly 3 times higher than at
a concentration of 10
-9 M (p = 0.0001). A similar pattern
was evident for calcipotriol, although alfacalcidol was
more potent in the assay.
We next isolated and expanded individual clones con-
taining the SB sensor inserted by the SB100X transpo-
sase. Twenty-one clones were grown in alfacalcidol-
containing medium (10
-5 M) and subsequently analyzed
Figure 2 Effective transposition of the tri-cistronic receptor-sensor SB DNA transposon in HaCaT cells. (A) Schematic representation of
the SB transposon-based sensor. Modules of the sensor are flanked by the left and right inverted repeat (LIR and RIR, respectively) of the SB
transposon. The 17-bp Upstream Activating Sequence quarto-repeat (UASx4) assists the minimal thymidine kinase (TK) promoter in expressing
the destabilized enhanced green fluorescence (d2eGFP) protein flanked by a Simian virus 40 (SV40) polyadenylation sequence. The selection
cassette consists of a SV40 promoter driving transcription of the neomycin resistance gene (Neo) tailed by a SV40 polyadenylation sequence. The
receptor component consists of the skin-specific keratin 14 (K14) promoter driving expression of the chimeric Gal4 human vitamin D receptor
(Gal4hVDR) gene flanked downstream by the K14 polyadenylation sequence. The K14 promoter restricts expression to keratinocytes and derived
cell lines or the stratum basale of the skin. (B) Genomic insertion of the genetic sensor catalyzed by a panel of transposases. The transposition
assay was carried out with various transposases at different concentrations. HaCaT cells were transfected with 1.7 μg pT2/UAS-d2eGFP.SV40-neo.
K14-Gal4hVDR and 300 ng, 50 ng or 15 ng plasmid encoding mSB, SB10, HSB3, HSB16 or SB100X. Additionally, 250 ng or 285 ng pUC19 was
included as stuffer to ensure that equal amounts of DNA were used in each transfection. Transposition activity was measured by counting the
number of G418-resistant colonies 14 days post-transfection. All experiments were performed in triplicates and are the data shown here as mean
values ± standard deviations.
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displayed a highly heterogeneous response to alfacalci-
dol. Hence, the amount of d2eGFP-positive cells ranged
from background level to 92.7% of the analyzed cells.
This clonal difference was paralleled by substantial
differences in mean fluorescence (figure 3B). This varia-
tion in responsiveness among individual clones offered
an explanation for the relatively low d2eGFP induction
level that was observed with pooled clones (figure 3A).
Based on their responsiveness to alfacalcidol, 10 clones
Figure 3 Generation of stable and highly inducible sensor clones with rapid increase and decline of signal. (A) Sensor induction in
HaCaT keratinocytes. HaCaT cells were co-transfected with 1.5 μg pT2/UAS-d2eGFP.SV40-neo.K14-Gal4hVDR and 0.5 μg pCMV-SB100X. Sensor-
containing cells were exposed to DMSO-dissolved vitamin D3 analogues at different concentrations for 48 hours and analyzed by flow
cytometry. (B) Induction of sensor in individual HaCaT clones. Cells were exposed to DMSO-dissolved 10
-5 M alfacalcidol and analyzed by flow
cytometry after 2 days. D2eGFP expression levels are shown in the first quadrant and mean FITC intensity in the second quadrant. Registered
signal in the FITC channel from un-transfected (naive) HaCaT cells served as reference. (C) Sensor activity in the absence and presence of drug.
Eight clones selected among the 21 sensor-containing clones were incubated 48 hours in absence or presence of 10
-5 M alfacalcidol and
subsequently evaluated by flow cytometry. (D) Southern blotting shows variable integration patterns among the vitamin D3-responsive clones.
(E) Kinetics of the sensor upon exposure to vitamin D3 analogues. Cells from clone #8 were initially split in two sets that were grown in parallel.
With regular time intervals medium containing 10
-5 M alfacalcidol was added to the cells. At 52 hours incubation one set was relieved from the
compound and cultured in drug-free media. At the end of the experimental time frame, the cells were analyzed by flow cytometry. The
experiments in (A), (B), and (E) were conducted in triplicate, and data are shown as mean values ± standard deviations.
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these 10 clones, clones #1 and #4 were impaired in
growth and survival and were discontinued. The remain-
ing 8 clones were examined in the absence or presence
of 10
-5 M alfacalcidol (figure 3C). For all clones, expres-
sion of d2eGFP was induced with statistical significance
by the presence of alfacalcidol relative to the no drug
control. However, the un-induced level of d2eGFP var-
ied considerably between clones, demonstrating some
leakiness that most probably was dependent on vector
copy number and the context of the insertion sites in
each individual clone.
Southern blot analysis of genomic DNA isolated
from the 8 clones unveiled SB vector copy numbers
ranging from 1 to approximately 10 copies per clone
(figure 3D). For some clones there was coherence
between the expression profile and copy number.
Clones #5 and #18 for example were characterized by
low and high sensor activity, respectively, correspond-
ing to the detection of 1 and numerous insertions in
the two clones, respectively. In other clones, high
d2eGFP expression was achieved with few copies of
the vector (e.g. clone #7 which had only 4 insertions),
whereas low expression could be detected in clones
with high copy numbers (e.g. clone #19). This sug-
gested that the receptor-sensor system was sensitive to
the properties of the insertion site perhaps due to var-
ied accessibility to the vector in non-permissive hetero-
chromatin and permissive euchromatin. Interestingly,
the single integration observed for clone #5 gave rise
to a significant increase in d2eGFP expression upon
alfacalcidol induction (p = 0.0007). This finding
demonstrated that the system can work in cis where a
ligand-activated sensor protein expressed from one
cassette in the SB vector can induce expression from
another cassette in the same vector, adding to the
notion of a highly sensitive system.
To get a better understanding of the system kinetics,
we periodically monitored d2eGFP expression in clone
#8 grown in the presence of 10
-5 M alfacalcidol (figure
3E). A measureable level was obtained already after 6
hours after the initial exposure to alfacalcidol followed
by a nearly linear increase in expression before reaching
a plateau about 60 hours after the initial induction. In
the presence of alfacalcidol the d2eGFP level remained
unchanged for the duration of the experiment (almost 4
days). However, removal of drug, resulting in an
expected gradual depletion of intracellular drug, caused
a simultaneous rapid decline of eGFP expression.
Hence, 39 hours after drug removal the d2eGFP level
had decreased by 63% (p = 0.0013). In conclusion, such
rapid onset and offset of d2eGFP expression allow expe-
ditious drug evaluation and sensitive sensoring of vita-
min D analogues.
Functional screening and comparison of vitamin D3
analogues by cell lines containing the SB-based genetic
drug sensor
To assess the potency of various vitamin D3 analogues,
some of which have not to date been approved for
therapeutic use, clones #7 and #18 were chosen for
additional experimentation. The clones were grown in
the presence of vitamin D3 analogues (diluted in 2-
PrOH) in concentrations ranging from 10
-9 Mt o1 0
-5
M. The cells were analyzed by flow cytometry after
two days of treatment with the agonist (figure 4). The
un-induced clone #18 (grown in the absence of drug)
provided the baseline d2eGFP level. Furthermore, all
settings and gates were identical for all measurements.
For both cell lines, all analyzed vitamin D3 analogues
resulted in induced d2eGFP expression although the
response in clone #18 in general was stronger than the
response in clone #7 (compare figures 4A and 4B).
This finding matched the previous observations for the
two clones (figure 3B and 3C). At the lowest applied
concentration (10
-9 M) EB1213, GS1590, and KH1230
showed a statistically significant elevated d2eGFP level
in clone #7 (p = 0,001, p = 0,001, p = 0,038, respec-
tively) with a similar tendency in clone #18. Thus, at
this low concentration as many as three analogues out-
performed the clinically used calcitriol and calcipotriol
in terms of reactivity and sensor induction. At 10
-7 M,
the difference in potency between the established com-
pounds, like alfacalcidol and calcipotriol, and the
remaining vitamin D3 variants became even more pro-
found. Under these conditions, the analogues EB1213
through KH1230 (as presented in figure 4) resulted in
a marked increase in d2eGFP expression levels. Inter-
estingly, EB1213 reached a level of expression that was
9 times higher than the level measured with calcipo-
triol (p = 0.0001) in clone #18. At the highest concen-
tration (10
-5 M) the differences in sensor induction
between the compounds was less clear and, notably,
calcitriol displayed the greatest effect under these
conditions.
A hallmark of vitamin D3 analogues in psoriasis ame-
lioration is the ability to inhibit proliferation of keratino-
cytes. To correlate sensor inducibility with their capacity
to inhibit cellular proliferation, we measured the half
inhibitory concentration (IC50) for each of the com-
pounds on HaCaT proliferation (Table 1). Interestingly,
we found a correlation between the magnitude of the
IC50 value and the inducibility of the genomically
inserted SB-derived sensor. Hence, these findings sug-
gest that this novel genetic sensor provides an efficient
method of screening new drugs and a quick clear indi-
cation of the therapeutic potency of vitamin D3 analo-
gues at the cellular level.
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Functional testing of new vitamin D3 analogues and for-
mulations for improved systemic and topical administra-
tion depends on sensitive screening methods that allow
evaluation of cellular uptake, functional intracellular
properties and, in case of topical administration, drug
delivery to the skin. In this study, we describe a new
approach for genetically sensoring the activity of vitamin
D3 analogues in keratinocytes or in any cell type of
interest. We establish an integratable reporter system,
Figure 4 Sensor-based screening of 10 vitamin D3 analogues revealed compounds more potent than therapeutically approved drugs.
(A) Efficacious sensor induction in clone #18. Cells derived from Clone #18 were exposed to vitamin D3 analogues at concentrations 10
-9 M, 10
-7 M
and 10
-5 M. As indicated below the chart, the vitamin D3 analogues had been dissolved in either isopropanol (2-PrOH) or DMSO. After 48 hours the
percentage of d2eGFP positive cells was measured by flow cytometry. Untreated (neg) cells served as control. A clear dose-dependent outcome is
visible for all drugs. The experiment was conducted in triplicate, and data are indicated as mean values ± standard deviations. (B) Sensor induction
in clone #7. Cells from clone #7 were treated as described for clone #18. The overall tendency is highly similar for clone #7 and #18.
Table 1 Coherence between sensor inducibility and cellular proliferation inhibition by the vitamin D3 analogues
Vitamin D3 compound
Calcitriol Alfacalcidol Atocalcitol Calcipotriol GS 1750 GS 1590 GS 1725 KH 1230 EB 1213
Relative IC50
-1 (1) 1.0 1.1 1.6 2.9 2.9 32.3 35.7 76.9 250
Relative potency
(2) Clone #18 1.0 0.6 2.7 1.0 7.2 7.9 6.0 5.5 9.2
Relative potency
(2) Clone #7 1.0 3.3 4.2 3.3 9.1 13.5 12.7 8.9 13.2
(1) The half maximal inhibitory concentration (IC50) is a measure of the capability of the compounds to inhibit proliferation of HaCaT cells. For a direct
comparison, the inverse value (IC50
-1) is depicted here normalized to the response obtained during calcitriol exposure. IC50 values were measured for drug
concentrations ranging from 10
-11 to 10
-7 M.
(2) The relative capacity of each compound to induce d2eGFP expression from the sensor is shown for each of the two clones #7 and #18 (data derived from
figure 4). Induction of d2eGFP was measured at a drug concentration of 10
-7 M.
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Page 8 of 13allowing rapid assessment and comparison of the
potency of vitamin D3 analogues, some of which are
currently in clinical use in treatment of psoriasis. The
genetic sensor features two functional components, a
vitamin D sensor protein consisting of the vitamin D
receptor fused to the DNA-binding domain of Gal4
(expressed from a keratinocyte-specific K14 promoter)
and a reporter module from which d2eGFP is expressed
under control of an inducible promoter containing four
copies of the UAS-element. This screening technology
takes advantage of the genome-integrating capacity of
the SB DNA transposon which facilitates accurate and
near-random genomic insertion of genetic cargo of
interest [40]. By mobilizing this tri-cistronic transposon-
based vector in cells of interest, it is possible to incorpo-
rate all elements of the genetic sensor, including the
sensor and reporter components and a selective marker
gene, in a single genomic locus, allowing easy incorpora-
tion of sensor functions in any cell type of interest.
Based on our interest in improving psoriasis treatment
and methods for analyzing the functional properties of
vitamin D3 analogues in keratinocytes, we generated
HaCaT keratinocyte cell lines with the genetic sensor
stably integrated by transposition mediated by the
hyperactive SB100X transposase [41,42]. Despite the fact
that the tri-cistronic transposon vector is fairly long
(8.3-kb) and, moreover, that HaCaT cells are difficult to
transfect, robust transposition of the genetic sensor was
easily achieved allowing production of stably transfected
cell lines. By utilizing the SB system, instead of relying
on random plasmid breakage and insertion by recombi-
nation, it was ensured that the expression cassettes were
undamaged during the insertion process. Among a
panel of transposase variants, the hyperactive SB100X
transposase was the most efficient. However, for this
particular transposase, we also observed an inhibitory
effect of increasing the amount of transpose-expressing
plasmid, indicating that transposition catalyzed by this
transposase in cultured keratinocytes is regulated by
overproduction inhibition. Such inhibition has pre-
viously been observed for all SB transposase variants
[43], but appear in hard-to-transfect cells to be evident
only for the most active transposases under the given
conditions.
Drug-resistant clones harboring the tri-cistronic trans-
poson vector were isolated and analyzed for the sensitiv-
ity of sensoring vitamin D derivatives. Among a group
of 21 clones analyzed for induction of d2eGFP expres-
sion, only 3 clones did not express the marker gene in
the presence of a vitamin D3 analogue. The remaining
clones responded after supplementation of analogues
but proved highly heterogeneous concerning the ability
to induce d2eGFP expression. To some degree, this fea-
ture may be attributed to variations in copy-number of
the tri-cistronic transposon vector (ranging from 1 to
approximately 10 copies) but may also reflect genomic
differences affecting gene expression from the sensor.
Importantly, we identified a single clone (#5) with a sin-
gle copy of the genetic sensor. Successful Vitamin D-
directed induction of d2eGFP expression in this clone
demonstrated that the genetic sensor was able to work
in cis and that one sensor module was sufficient to
obtain a detectable readout.
A dose-dependent response to the addition of alfacal-
cidol and calcipotriol could be recorded within a range
of drug concentrations used in previous functional stu-
dies of vitamin D3 analogues [6,44,45]. Other Gal4-
receptor hybrids also exhibited dose-responsiveness [46],
emphasizing the dynamic working range of the Gal4-
UAS system and its suitability for drug comparative stu-
dies. The dose-response assay showed evidence of a
rapid onset of d2eGFP signal upon cell exposure to vita-
min D3 analogues, which is in the interest of a sensitive
and rapid drug screening methodology. More impor-
tantly, information regarding the exact time of onset,
slope and peak intensity induced by exposure to the
drug allows comparative analyses of functional proper-
ties related to the kinetic nature of a given drug and its
cellular permeability. By tracking the decline in d2eGFP
expression after drug removal one may provide insight
into the stability of the VDR-RXR-UAS complex and
bioavailability of the drug.S u c hp r o p e r t i e sm a yg i v e
comparative indications of drug clearance by metabo-
lism or sequestering by endogenous proteins.
Genetic sensoring represents a new approach for func-
tional screening of synthetic derivatives of vitamin D3.
To demonstrate such potential, we screened eight differ-
ent vitamin D3 analogues, some of which are currently
used in psoriasis treatment and some of which are more
recently developed drugs. By using two highly respon-
sive HaCaT cell line clones (#7 and 18) harboring four
or more copies of the genetic sensor, we identified a
group of compounds which activated the sensor very
potently. Notably, by use of the two clones quite similar
activation patterns were seen for each of the tested
compounds. Several of the tested compounds were
found to activate the sensor with higher efficiency than
current drugs like calcitriol and calcipotriol. This differ-
ence was evident at the lower drug concentrations, sup-
porting the notion that these drugs may efficiently bind
and promote a beneficial conformational change of the
VDR in keratinocytes. Such increased activation of the
sensor was paralleled by an increased capacity of these
particular drugs to inhibit proliferation in HaCaT cells,
as demonstrated by increased IC50
-1 values for all these
drugs. It is important to note that the growth inhibitory
effect for keratinocytes in vitro does not prevail until 4-
6 days after addition of the drug and therefore is not
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ever, high potency to activate the vitamin D receptor or
inhibiting keratinocyte proliferation, are only some para-
meters to consider before selecting a novel vitamin D3
analogue for further drug development.
The specific properties that enable a given vitamin D3
analogue to perform superior to calcitriol may fall into
three categories (i) alterations in the pharmacodynamics
including increased affinity for VDR, prolonged stability
of the receptor-DNA complex, a changed receptor con-
formation or epigenetic changes, (ii) pharmacokinetic
influences like improved half-life through a slower meta-
bolic clearance, diminished absorption by cellular factors
such as serum vitamin D binding protein (DBP) result-
ing in higher bioavailability, and improved cellular
access, or (iii) pharmacogenetic aspects including tran-
scriptional changes and alterations in the cellular envir-
onment. In addition, secondary effects that are not
mediated by the transcription-factor activity of VDR
may also be involved. Hence, e.g. the Raf1-MAPK path-
way which plays a pivotal role in the mechanism of ker-
atinocyte growth is stimulated by calcitriol. Thus, before
selecting a novel vitamin D3 analogue for drug develop-
ment, several different aspects and properties of a com-
pound must be considered. The genetic sensor for in
vitro assessment of VDR activation may address some of
these parameters as rapid functional selection among a
large library of new potential drugs. Vitamin D deriva-
tives with high sensor activation capacity may subse-
q u e n t l yb ef u r t h e rs c r u t i n i z e di nm o r ee l a b o r a t e
experimental settings including keratinocyte inhibitory
studies and protein interaction studies. However, to ver-
ify if such findings in vitro have any relevance, a more
subtle in vivo assessment may be necessary, for example
in preclinical studies using appropriate animal models
[47]. One such model is the xenograft transplantation
model in which human psoriatic skin is grafted onto
immunodeficient mice, allowing assessments of various
systemic and topical treatments [48,49].
Implementation of the sensor technology in animal
studies may provide new opportunities for combined
studies of VDR modulation and drug kinetics and deliv-
ery. Numerous transgenic animals have been generated
by use of the SB transposon system, [41,50,51], making
it reasonable to envision production of sensor-transgenic
animals. Recently, we demonstrated the use of SB trans-
poson vectors for transgenesis of cloned Göttingen
minipigs [52], paving the way for introduction of SB-
based genetic sensors in the pig. Given the fact that the
skin of pigs has many anatomical and physiological simi-
larities with human skin, the establishment of an animal
model for genetically sensored vitamin D delivery and
permeability in skin may have a strong potential in stu-
dies of drug delivery and novel drug formulations with
relevance for topical treatment in humans. With the
rapidly emerging applications of vitamin D3 analogues
in treatment of human diseases, including cardiovascular
diseases, inflammatory disorders, and cancer, the inter-
est in a sensitive in vivo screening approach should not
be restricted to topical drug administration and psoria-
sis. Notably also, the VDR component of the system
that we describe herein is easily interchangeable with
other receptors of interest, making the concept of an
integratable sensor approach highly versatile.
Conclusions
We demonstrate the use of a DNA transposon-based
genetic sensor system, allowing for rapid functional
screening of vitamin D3 analogues in an in vitro setting.
The sensor module was easily inserted into the genome
of keratinocytes, allowing comparative functional studies
of vitamin D3 analogues in a keratinocyte background.
HaCaT cells stably expressing the sensor and reporter
components of the sensor showed potent activation of
the sensor in a fashion that was dependent on the drug
and its concentration, thereby facilitating assessment of
drug kinetics and dynamics. A total of eight analogues
were tested against the active form of vitamin D3 (calci-
triol). Several of the analogues proved more potent than
calcitriol and exhibited significant signal to noise ratios
even at low concentrations (10
-9 M). Due to the in-built
possibility of exchanging each component individually,
the sensor system can be adapted to accommodate
other receptors of interest and/or possess an alternative
cell-specific expression profile, with the potential of
enabling high-throughput screening of candidate drugs
in a time-saving and cost-effective manner. The creation
of genetically engineered animals transgenic for the
genetic sensor will pave the way for in vivo investiga-
tions of drug potency and administration, allowing for
more elaborate comparative studies of vitamin D3
analogues.
Methods
Generation of a tri-cistronic receptor-sensor construct
All the basic plasmids (pUAS-tk-luc (57), pd2eGFP1
(Clontech Laboratories, Inc., Mountain View, CA, USA),
pM (Clontech Laboratories, Inc., Mountain View, CA,
USA) and pG3Z-K14 [53]) were present in house and
the pSG5-VDR plasmid was provided by courtesy of Leo
Pharma, Denmark. pT2/SV40-neo has previously been
described [54]. pT2/SV40-neo was initially modified to
remove the restriction sites SacI (position 107) and Hin-
dIII (position 404), and PmeI and SacI sites were intro-
duced at position 413 and 2069, respectively. The UAS-
tk promoter was released from pUAS-tk-luc by PvuII/
XhoI digestion and inserted into Ecl36II/SalI-digested
pd2eGFP1. The resulting UAS-tk-d2eGFP was PCR-
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resulting in the construct designated pT2/UAS-d2eGFP.
SV40-neo. A fragment containing hVDR was PCR-
amplified from pSG5-VDR and cloned into EcoRI/XbaI-
digested pM. The resulting Gal4hVDR module was
released by AvrII/XbaI digestion and incorporated in
XbaI-digested pG3Z-K14. The K14-Gal4hVDR fragment
was isolated by SacI/HindIII digestion and inserted into
SacI/HindIII-digested pT2/UAS-d2eGFP.SV40-neo
resulting in the final sensor construct designated pT2/
UAS-d2eGFP.SV40-neo.K14-Gal4hVDR.
Generation of cell clones expressing the sensor
components
For stable and transient transfections, HaCaT or
HEK293 cells were seeded in 6-well plates at a density
of 2 × 10
5/well. The preceding day the cells were trans-
fected using Fugene 6 (Roche, Basel, Switzerland)
according to manufacturer’s protocol utilizing a 6 μL:2
μg fugene:total plasmid ratio for HaCaT and 3 μL:2 μg
for HEK293 cells. The following day the cells were re-
seeded in P10 dishes at varying dilutions. After another
24h, the cells were subjected to G418 (Invitrogen Ltd,
Paisley PA4 9RF, UK) selection (0,6 mg/mL) for 14
days. Subsequently, the resistant colonies were either
stained with methylene blue (Sigma-Aldrich, St. Louis,
MO, USA) for transposition efficiency assays or pooled
or isolated for system evaluations.
RT-qPCR on pooled sensor-containing clones
HaCaT cells were transfected as described above; 1.5 μg
pT2/UAS-d2eGFP.SV40-neo.K14-Gal4hVDR (or pT2/
SV40-neo.K14-Gal4hVDR) + 0.5 μg pCMV-SB100X, the
latter expressing the SB100X transposase. RNA from
G418-resistant colonies was extracted through a spin-col-
umn (RNeasy Kit, QIAGEN, Valencia CA, USA) accord-
ing to manufacturer’s instructions. Extracted RNA was
DNase-treated (DNA-free, Ambion, Foster City, CA
USA) in accordance with protocol. 100 ng DNA-free
RNA was subsequently utilized in the cDNA synthesis
(Bio-Rad, iScript cDNA synthesis kit, Hercules, CA,
USA). Two μL of the cDNA synthesis mix was employed
in the qPCR reaction together with 6 pM Gal4 primer:
5’-AGTGCTCCAAAGAAAAACCGA-3’ (forward) and
Gal4 primer: 5’-GGTCTTCTCGAGGAAAAATCAG-3’
(reverse) or ACTB primer: 5’-CTGGCACCACACCTTC-
TACA (forward) and ACTB primer: 5’-GGTCATC
TTCTCACGGTTGG-3’ (reverse) and 10 μLm a s t e r m i x
(DyNAmo HS SYBR Green qPCR kit, Finnzymes, Espoo,
Finland). Amplification was conducted on a Roche Light-
Cycler 480 under the following conditions: 1 × 95°C for 5
min; 45 × 95°C for 20 sec, 55°C for 20 sec, 72°C for 30
sec; continuous melting. Ct values were calculated from
the “Fit Point Method” and relative quantification was
conducted by normalization to the housekeeping gene
ACTB (R = 2
ΔCtsample/2
ΔCtreference).
Southern blot analysis
Genomic DNA was prepared from cell pellets following
NaCl extraction and ethanol precipitation. 15 μgg e n o -
mic DNA was digested overnight with NheI (a single
site within the transposon) and PvuI (cleaves within the
bacterial backbone, resulting in a distinct band with a
l e n g t ho f4 5 8 5b pi nc a s eo fp l a s m i dD N A ) .G e n o m i c
DNA of non-transfected cells was used as a negative
control. Genomic DNA of non-transfected cells spiked
with plasmid DNA corresponding to 1 copy/cell (32 pg
plasmid DNA), 3 copies/cell (96 pg plasmid DNA), or
10 copies/cell (320 pg plasmid DNA) was used as a
positive control. The digested DNA was electrophoresed
in a 0.8% agarose gel and transferred to a Hybond mem-
brane (GE Healthcare, Buckinghamshire, UK). The
membrane was hybridized overnight using a Neo-speci-
fic [a-32P] dCTP-labelled probe.
Flow cytometry and dose-response analysis on sensor-
harboring cells
Clones containing the integrated sensor system were
seeded in 24-well plates at a density of 2 × 10
4 cells/
well and maintained in DMEM 10% FCS at 37°C and
5% CO2. For induction assays, vitamin D3 analogues
(concentrations ranging from 10
-9 to 10
-5 M) were
added after 24 h and left for additional 48 h. In the
dose-response assay, the vitamin D3 analogue (10
-5 M)
was added at different time points. The drug was either
left on the cells for the duration of the experiment or
removed at various time points commenced after 48 h
of induction. For flow cytometry, the cells were trypsi-
nized and resuspended in 500 μLP B S( n oM g C l 2,n o
CaCl2)a n da d d e d4μg/mL (final concentration) propi-
dium iodide (Sigma-Aldrich, St. Louis, MO, USA). Sub-
sequently, 10,000 events were analyzed on a BD
FACSAria machine using BD FACSDiva software. In all
experiments measuring drug-induced gene activation, a
negative control group (naïve) was included. Cells in
this group were grown in normal medium without addi-
tion of 2-PrOH or DMSO.
Vitamin D drugs
Calcitriol [55] and vitamin D3 analogues (alfacalcidol
[56], calcipotriol [57], atocalcitol, EB1213 [1,14], GS1590
[58], GS1725 [14], GS1750 (unpublished), KH1230 [59])
were either dissolved in 2-PrOH at 4 mM or DMSO at
10 mM.
Assessment of drug-induced cell death
Non-transfected HaCaT cells were seeded in 6 well
plates at 100 cells per well. After 3 days in medium with
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-7 to 10
-4 M) of
calcipotriol or alfacalcidol was supplied. After an addi-
tional 5 days the surviving colonies were stained with
methylene blue and counted. A kill-curve was con-
structed with untreated cells as reference.
Proliferation inhibitory assay
HaCaT cells were propagated in Phenol Red-free Dul-
becco’s modified Eagle’s medium supplemented with 5%
FCS, 2 mM glutamine, 100 IU/mL penicillin, and 100
pg/mL streptomycin. The cells were incubated in a
humidified atmosphere at 37°C in the absence and pre-
sence of the test compounds (10
-11 to 10
-7 M). After
120 hr of incubation, DNA synthesis was determined by
incorporation of
3H-labelled thymidine. Each sample
was tested in quadruplicate, and the concentration of
test compound resulting in 50% inhibition (IC50)o f
DNA synthesis was calculated from the dose-response
curve.
Statistical analysis
All p-values were calculated by a two-tailed Student’st -
test to test the null hypothesis of no difference between
the compared groups. The assumption of equal var-
iances was tested by the F-test. In all statistical analyses,
p-values < 0.05 were considered significant.
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